Clinical trials: sponsored by NRG Oncology
Anaplastic Astrocytoma, Glioblastoma
Testing the Addition of an Anti-cancer Viral Gene Therapy, Toca 511/Toca FC, to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed Glioblastoma
This phase II/III trial studies how well vocimagene amiretrorepvec (Toca 511) and extended release flucytosine (Toca FC) work when added to the usual treatment (temozolomide and radiation therapy) in treating patients with newly…
- Conditions
- Anaplastic Astrocytoma, Glioblastoma, Oligodendroglioma, Supratentorial Glioblastoma
- Trial name
- NCT04105374
- Testing
- Extended Release Flucytosine, NovoTTF-100A Device, Quality-of-Life Assessment
- Sponsor
- NRG Oncology
Breast Adenocarcinoma, Estrogen Receptor Negative
Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer
This randomized phase III trial studies how well doxorubicin hydrochloride and cyclophosphamide followed by paclitaxel with or without carboplatin work in treating patients with triple-negative breast cancer.
- Conditions
- Breast Adenocarcinoma, Estrogen Receptor Negative, HER2/Neu Negative, Progesterone Receptor Negative
- Trial name
- NCT02488967
- Testing
- Carboplatin, Cyclophosphamide, Doxorubicin Hydrochloride
- Where
- 1,296 sites in United States, Canada
- Volunteers
- 782 people
- Sponsor
- NRG Oncology
HER2-positive Breast Cancer
Testing Radiation and HER2-targeted Therapy Versus HER2-targeted Therapy Alone for Low-risk HER2-positive Breast Cancer
This Phase III trial compares the recurrence-free interval (RFI) among patients with early-stage, low risk HER2+ breast cancer who undergo breast conserving surgery and receive HER2-directed therapy, and are randomized to not…
- Trial name
- HERO (NCT05705401)
- Testing
- Standard of Care Adjuvant Breast Radiation, Standard of Care HER2-targeted Therapy Without Adjuvant Breast Radiation
- Where
- 418 sites in United States, Puerto Rico
- Volunteers
- 1,300 people
- Sponsor
- NRG Oncology
Stage I Breast Cancer
De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)
This Phase III Trial evaluates whether breast conservation surgery and endocrine therapy results in a non-inferior rate of invasive or non-invasive ipsilateral breast tumor recurrence (IBTR) compared to breast conservation with…
- Trial name
- DEBRA (NCT04852887)
- Testing
- Radiation and Endocrine Therapy (Tamoxifen, Anastrozol, Letrozole, Exemestane), Endocrine Therapy (Tamoxifen, Anastrozol, Letrozole, Exemestane)
- Where
- 832 sites in United States, Canada and 2 more
- Volunteers
- 1,670 people
- Sponsor
- NRG Oncology
Low Grade Fallopian Tube Serous Adenocarcinoma, Ovarian Low Grade Serous Adenocarcinoma
Letrozole With or Without Paclitaxel and Carboplatin in Treating Patients With Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
This phase III trial studies how well letrozole with or without paclitaxel and carboplatin works in treating patients with stage II-IV low-grade serous carcinoma of the ovary, fallopian tube, or peritoneum.
- Conditions
- Low Grade Fallopian Tube Serous Adenocarcinoma, Ovarian Low Grade Serous Adenocarcinoma, Primary Peritoneal Low Grade Serous Adenocarcinoma, Stage II Fallopian Tube Cancer AJCC v8
- Trial name
- NCT04095364
- Testing
- Biopsy Procedure, Biospecimen Collection, Carboplatin
- Where
- 909 sites in United States, Canada and 4 more
- Volunteers
- 450 people
- Sponsor
- NRG Oncology
Stage II Prostate Adenocarcinoma AJCC v7
Stereotactic Body Radiation Therapy or Intensity-Modulated Radiation Therapy in Treating Patients With Stage IIA-B Prostate Cancer
This randomized phase III trial studies how well stereotactic body radiation therapy works compared to intensity-modulated radiation therapy in treating patients with stage IIA-B prostate cancer.
- Trial name
- NCT03367702
- Testing
- Intensity-Modulated Radiation Therapy, Quality-of-Life Assessment, Questionnaire Administration
- Where
- 293 sites in United States, Canada and 4 more
- Volunteers
- 692 people
- Sponsor
- NRG Oncology
Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma
Ruxolitinib Phosphate, Paclitaxel, and Carboplatin in Treating Patients With Stage III-IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
This phase I/II trial studies the side effects and the best dose of ruxolitinib phosphate when given together with paclitaxel and carboplatin and to see how well they work in treating patients with stage III-IV epithelial…
- Conditions
- Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube High Grade Serous Adenocarcinoma, FIGO Stage III Ovarian Cancer 2014
- Trial name
- NCT02713386
- Testing
- Carboplatin, Paclitaxel, Ruxolitinib Phosphate
- Where
- 110 sites in United States
- Volunteers
- 147 people
- Sponsor
- NRG Oncology
Invasive Breast Carcinoma, Stage II Breast Cancer
Assessing the Accuracy of Tumor Biopsies After Chemotherapy to Determine if Patients Can Avoid Breast Surgery
This phase II trial studies how well biopsy of breast after chemotherapy works in predicting pathologic response in patients with stage II-IIIA breast cancer undergoing breast conserving surgery.
- Conditions
- Invasive Breast Carcinoma, Stage II Breast Cancer, Stage IIA Breast Cancer, Stage IIB Breast Cancer
- Trial name
- NCT03188393
- Testing
- Biopsy of Breast
- Where
- 381 sites in United States, Canada
- Volunteers
- 105 people
- Sponsor
- NRG Oncology
Colon Adenocarcinoma, Stage IIA Colon Cancer AJCC v8
Circulating Tumor DNA Testing in Predicting Treatment for Patients With Stage IIA Colon Cancer After Surgery
This phase II/III trial studies how well circulating tumor deoxyribonucleic acid (ctDNA) testing in the blood works in predicting treatment for patients with stage IIA colon cancer after surgery.
- Trial name
- NCT04068103
- Testing
- Capecitabine, Fluorouracil, Leucovorin
- Where
- 957 sites in United States, Canada and 1 more
- Volunteers
- 635 people
- Sponsor
- NRG Oncology
Endometrial Endometrioid Adenocarcinoma, Endometrial Mixed Cell Adenocarcinoma
Copanlisib in Treating Patients With Persistent or Recurrent Endometrial Cancer
This phase II trial studies how well copanlisib works in treating patients with endometrial cancer that has not decreased or disappeared, and the cancer may still be in the body despite treatment (persistent) or has come back…
- Conditions
- Endometrial Endometrioid Adenocarcinoma, Endometrial Mixed Cell Adenocarcinoma, Endometrial Serous Adenocarcinoma, Endometrial Undifferentiated Carcinoma
- Trial name
- NCT02728258
- Testing
- Copanlisib, Laboratory Biomarker Analysis
- Where
- 43 sites in United States
- Volunteers
- 11 people
- Sponsor
- NRG Oncology
Endometrial Serous Adenocarcinoma, Fallopian Tube Carcinoma
Comprehensive Patient Questionnaires in Predicting Complications in Older Patients With Gynecologic Cancer Undergoing Surgery
This research trial studies comprehensive patient questionnaires in predicting complications in older patients with gynecologic cancer undergoing surgery.
- Conditions
- Endometrial Serous Adenocarcinoma, Fallopian Tube Carcinoma, Malignant Female Reproductive System Neoplasm, Ovarian Carcinoma
- Trial name
- NCT02315469
- Testing
- Comprehensive Geriatric Assessment, Questionnaire Administration
- Where
- 393 sites in United States, Canada
- Volunteers
- 190 people
- Sponsor
- NRG Oncology